Company news

Vistagen Therapeutics, Inc. news in 2021

Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update

November 9, 2021

VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021

November 3, 2021

VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder

October 13, 2021

VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B’s Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain

October 4, 2021

VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2

September 12, 2021

VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update

August 11, 2021

VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors

July 21, 2021

VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors

July 6, 2021

VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update

June 28, 2021

VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021

June 24, 2021

VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder

May 25, 2021

VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer

May 3, 2021

VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors

April 26, 2021

VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021

February 10, 2021

VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements

January 5, 2021

Calls in 2021

Decks in 2021